NCT01950182View on ClinicalTrials.gov

Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

392

Participants

Timeline

Start Date

September 16, 2013

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions

Breast Cancer

Interventions

DRUG

Endocrine therapy combined with trastuzumab

Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab

DRUG

Chemotherapy combined with trastuzumab

Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT01950182 - Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer | Biotech Hunter | Biotech Hunter